Non-coding mutations in the GRN gene that reduce the levels of PGRN by ~10 to 20 percent are associated with an increased risk for AD [64,135,136], PD [137], ALS [138], and limbic-predominant age-related TDP-43 encephalopathy (LATE) [139]. This evidence concerns the gene GRN and Alzheimer disease.